Developed Countries
Financial stocks have risen in sympathy with the back up in global bond yields, but that likely represents position squaring more so than a sustained shift into the sector. Financial profits will continue to be challenged by a downturn in the credit cycle, both in terms of quality and loan creation, given the negative global credit impulse and flattening yield curve (shown inverted and advanced, bottom panel). Importantly, productivity is waning. Financial sector employment is probing new highs, reflecting a more onerous cost structure required to meet regulatory obligations. Employment is now growing faster than sales (third panel), a reliable indication of flagging productivity. The implication is that financial sector profits will continue to lag those of the broad market. We continue to view cheap financial sector valuations as a trap, and recommend below benchmark positions.
A reduction in the rate of drug price increases, and in the case of generics, outright price cuts, is a blessing for the S&P managed care industry. Cost inflation had been perking up, but should ease in the coming quarters as drug expenses abate. Health insurance premiums are growing at a faster rate than overall inflation, while job growth remains decent, underscoring that top-line growth is still outpacing that of the overall corporate sector. If cost inflation eases while revenue climbs, the index should move to at least a market multiple from its current discounted valuation. Importantly, technical readings have improved. Cyclical momentum has begun to reaccelerate from neutral levels after unwinding overbought conditions, suggesting that a breakout to new relative performance highs is in the offing. Bottom Line: the pain in drug-related shares should provide a gain to health care insurers. Stay overweight.
A number of drug wholesalers have reported earnings misses and provided disappointing guidance, specifically citing worse than expected generic drug pricing pressure, enough to offset ongoing branded drug price increases. In the current environment of political uncertainty toward health care companies, the knee jerk reaction has been to abandon all pharmaceutical-related equities, regardless of exposure to branded or generic medicines. Our pharmaceutical equity view has noted that the time to worry about the pace of drug price increases would be if they sparked a change in consumption patterns and/or buyer behavior. The fact that major buying groups such as health insurers and pharmacy benefit managers are balking at generic drug price increases constitutes such a shift. Consumer spending on drugs has slowed, albeit that has neither been confirmed by still strong retail drug store sales nor booming hospital employment. Nevertheless, in light of new information, which implies that company disclosed pricing pressure is worse than current government data show, we are downgrading our outlook for drug-related shares. However, rather than sell after the index has already taken a large hit, pushing relative performance to oversold and undervalued levels, we will await a more opportune moment to lighten positions, especially in view of our preference for defensive equities. In the meantime, the S&P pharma and biotech indexes are now on downgrade alert and the overall health care sector is off our high-conviction list. The good news is that other parts of the health care sector should benefit, see the next Insight.
Highlights U.S. Corporates: U.S. corporate debt, both Investment Grade and High-Yield, is fully priced for an improvement in economic growth and profits. Tight valuations offer no yield cushion before the expected December Fed rate hike. Maintain a defensive up-in-quality stance on U.S. corporates, favoring Investment Grade over junk. Euro Area Corporates: Euro Area corporate bonds are not as expensive as U.S. equivalents, but are by no means cheap. The likely extension of the ECB QE program until at least the latter half of 2017 will help keep valuations at rich levels, especially for Investment Grade issuers where the ECB is directly buying bonds. Stay defensive in Euro Area corporates, favoring Investment Grade over High-Yield. Feature Better Global Growth Not Necessarily Better For Corporate Bonds Back in July of this year, BCA put its flag in the ground and called an end to the 35-year global bond bull market after government bond yields hit historic lows following the shocking U.K. Brexit vote.1 Yields have steadily crept up since we made that declaration, due to a combination of changing cyclical factors (improving global growth, modest increases in inflation), some signs of diminished political concerns (no immediate global spillovers from a more drawn-out Brexit process, the fall in the odds of victory of the "anti-status-quo" candidate in the U.S. presidential election, Donald Trump) and structural factors (worries about less accommodative monetary policies, a political shift towards greater deficit-financed government spending). While government bond yields have been rising from depressed levels, corporate bond returns on either side of the Atlantic Ocean have at the same time lost considerable momentum, both in absolute terms and relative to sovereign debt (Chart of the Week). This is a bit of a surprise given the recent improvement in global growth data that is now appearing in a broadening number of countries (Chart 2), which would suggest a potential brighter outlook for corporate earnings. However, credit valuations and the liquidity backdrop matter, and a potential cyclical improvement in profits may not benefit corporate bond performance at a time of tight spreads and greater uncertainty about future central bank policies. Chart of the WeekIs The Party Ending For Corporate Bonds? Chart 2A Broadening Pickup In Global Growth With credit spreads currently priced for a near-perfect backdrop of low volatility and highly accommodative central banks, we continue to recommend an overall defensive posture in "Trans-Atlantic" corporate bonds, favoring Investment Grade (IG) over High-Yield (HY) in both the U.S. and Euro Area. Chart 3U.S. Corps Are Now ONLY A 'Tina' Trade U.S. Corporates: Stretched Valuations, Especially For Junk Bonds U.S. corporate bonds have been one of the biggest beneficiaries of the so-called "TINA" (There Is No Alternative) trade, where investors have been forced into riskier assets out of low-yielding government bonds. The return performance for both investment grade (IG) and high-yield (HY) debt has been outstanding, with the former up 8.2% year-to-date and the latter up +15.9%. The fundamental backdrop for corporate debt, however, has shown few signs of any improvement that would justify such strong returns, according to our U.S. Corporate Bond Checklist (Chart 3): 1.Corporate balance sheets are deteriorating: Our U.S. Corporate Health Monitor (CHM), an amalgamation of various bottom-up credit metrics applied to top-down corporate profit data, continues to signal that balance sheets are worsening. This trend has been ongoing for more than two years and shows no signs of slowing, with companies continuing to ramp up leverage to record highs at a time of increasing downward pressure on profit margins. 2.Bank lending standards are slowly tightening: The U.S. Federal Reserve's Senior Bank Loan Officer Survey has begun to flash that a greater number of U.S. banks are tightening lending standards on commercial & industrial loans. The net number is still low within the history of this series, and is largely the result of tightening standards on domestic energy companies suffering from the lower oil prices of the past two years. Nonetheless, the highly cyclical nature of lending standards suggests that a move back to easier standards may not happen at this advanced stage of the multi-year credit cycle. 3.Monetary conditions are tighter, but remain stimulative: Our U.S. Monetary Conditions Index (MCI), which is a weighted combination of short-term interest rates and the U.S. dollar, remains at an accommodative level, even after the 18% rise in the trade-weighted dollar since the trough in 2014 and the Fed's lone rate hike last year.2 Interest rates are far more important in our MCI calculation than the dollar (by a 10/1 ratio), however, so it would take an exceptionally large move in the dollar to push the MCI to restrictive territory after just a single 25bp rate hike. Yet with the Fed clearly in a slow hiking cycle that could deliver at least another 75bps of rate hikes by the end of 2017, the MCI will continue in a tightening direction that has historically been correlated with wider corporate bond spreads. With only an easy money backdrop supportive of narrower credit spreads, there is a growing risk that U.S. corporates could respond poorly to a December Fed rate hike that we expect - especially if that also coincides with renewed strength in the U.S. dollar. Already, the Fed's trade-weighted dollar index has risen by 3.2% during the recent Treasury market selloff, as the market-determined probability of a December hike has risen to 66%. This remains below the peaks seen in the run-up to the rate hike at the end of 2015, which coincided with a big widening of corporate credit spreads (Chart 4). One major difference from a year ago is that the Fed is not signaling the same degree of monetary tightening after the next hike. The FOMC median interest rate projections (the "dots") were indicating another 100bps of hikes following the December 2015 rate increase, and are now only signaling another 50bps of hikes after the Fed's expected next move in December. This is keeping both the 2-year Treasury yield and the dollar well below the peaks seen at the end of last year, helping prevent a breakout in market volatility and credit spreads. So if there is a fresh spike in volatility and/or the dollar, it would be striking the corporate credit markets at a time when valuations look stretched. We can see that in a number of indicators. U.S. corporate bond excess returns have far exceeded the levels suggested by domestic capacity utilization, which are relevant for corporates given their long-standing correlation to profit margins (Chart 5). Our colleagues at our sister publication, U.S. Bond Strategy, have calculated that a 0.4% improvement in capacity utilization has historically coincided with a 100bps tightening in HY bond spreads over a 1-year period; thus, utilization would have to rise to 77.2% by next February (a level last seen in March 2015 when the annual growth rate of Industrial Production was 2.5 percentage points faster than the current pace) to justify HY spreads at current levels.3 In other words, junk bonds are already priced for a significant recovery in U.S. economic growth and corporate profits. Chart 4U.S. Corps Not Responding To A Rising USD...Yet Chart 5Ignoring The Signal From Capacity Utilization U.S. corporate bond excess returns over duration-matched Treasuries during the past twelve months have been strongly positive: +316bps for IG and +844bps for HY. Our past work analyzing U.S. credit cycles has shown that such a positive return performance usually occurs during the deleveraging stage of the corporate credit cycle, typically during recessions when profits are falling and growth in company debt stalls or even contracts (Charts 6 & 7). Chart 6Investment Grade Corporate Annual Excess Return* Chart 7High-Yield Annual Excess Return* Chart 8Spreads Ignoring The Usual Credit Cycle The current environment is one of declining corporate profits but with debt growth still expanding, similar to the credit spread widening backdrop around the 2000 and 2008 U.S. recessions (Chart 8). This sends a similar message to the relationship of credit returns with capacity utilization, with corporate bonds now priced for a strong rebound in profit growth that may be difficult to achieve over the next year. A similar situation exists in the equity market, where the consensus bottom-up expectation is for overall profit growth to surge to +13% in 2017 and +11% in 2018.4 That would represent a sharp rebound from the profit declines witnessed in 2015 and the first half of 2016. Chart 9A Stretched Rally In U.S. Junk Some may argue that such a significant rebound in overall corporate earnings could happen just from the impact of better outlook for profits in the Energy sector given the recent recovery in oil prices. However, it appears that U.S. corporate bond valuations already more than fully discount a higher crude price. The 2016 rally in U.S. junk bonds has been led by the massive tightening of spreads of oil-related names, with the benchmark Bloomberg Barclays High-Yield Energy index returning 33% year-to-date as spreads have collapsed. However, the current Energy index OAS is at 550bps - levels last seen during the 2015 counter-trend rally in oil prices after the 2014 plunge (Chart 9, middle panel) That rally took the Brent crude price of oil up to $67/bbl, well above the current price hovering around $50/bbl. Our Commodity strategists continue to see $60/bbl as being the ceiling for the oil price range over the next year, as prices above that would begin to draw supply back into the market from U.S. shale companies and other global oil producers with higher break-even prices. Thus, U.S. HY energy debt already discounts an oil price that is unlikely to be achieved in the medium-term. A similar situation exists when looking at non-Energy junk spreads, which are highly correlated with macro volatility measures like the VIX index and which already fully reflect the current low volatility backdrop (Chart 9, bottom panel). We are concerned about a pick-up in volatility in the near-term from either a political surprise like a Trump victory on November 8 or, more likely, market jitters when the Fed delivers on a rate hike in December. With our fundamental VIX model, which is based off the lagged impact of rising corporate leverage and tightening monetary conditions, continuing to signal that the fair value level of the VIX is around 20, credit markets are not prepared for a potential rise in volatility in the next few months. Challenging Valuations At All Levels When we look at our various valuation gauges for U.S. corporate debt, it is difficult to find many areas where credit looks cheap. With regards to IG debt, our preferred measure of valuation is the 6-month breakeven spread, which shows how much spreads would need to widen to full offset the carry advantage of owning IG debt over duration-matched U.S. Treasuries, assuming spread volatility is maintained at recent levels. That breakeven spread now sits at a mere 9bps (Chart 10, top panel), well below the long-run mean. In other words, IG excess returns can easily turn negative with only a modest widening of spreads. For HY debt, our preferred valuation metric is the default-adjusted spread, where we subtract expected default losses estimated by our default rate and recovery rate models from the current junk spread. That adjusted spread is now only 69bps - a level more than one standard deviation below the long-run mean that we consider to be overvalued (bottom panel). With spreads at such depressed levels relative to expected default losses, the historical probability of junk delivering positive excess returns over the next year is extremely low. We see a similar stretched valuation backdrop when looking at credit spreads among sectors and ratings cohorts. Within the IG universe, the OAS for Financials, Industrials and Utilities have fully converged (Chart 11, top panel), while credit spread curves are near the tranquil 2005-2007 period of historically low volatility that we do not expect to be repeated (bottom panel). Within sectors, our U.S. IG relative value model only sees attractive spreads in the debt of Banks, Energy, Metals & Mining, Building Materials, Technology and Airlines. Chart 10Expensive Valuations, Especially For Junk Chart 11Not Much Difference To Choose From Here Bottom Line: U.S. corporate debt, both Investment Grade and High-Yield, is fully priced for an improvement in economic growth and corporate profits. Tight valuations offer no yield cushion before the expected December Fed rate hike. Maintain a defensive up-in-quality stance on U.S. corporates, favoring Investment Grade over junk. Euro Area Corporates: ECB Buying Keeping IG Rich While Junk Fundamentals Worsen Turning towards Europe, a similar story of expensive corporate credit valuations exists, although not to the same magnitude as in the U.S. Of course, valuations may not matter for Euro Area IG with the European Central Bank (ECB) buying corporate debt as part of their quantitative easing (QE) asset purchase program. That surge in QE buying (both real and anticipated by investors) helped drive both yields and spreads for Euro Area IG sharply lower between March and June of this year. Since then, however, both yields and spreads have gone up moderately (Chart 12), reflecting both the rising global yield backdrop and the worsening situation for Euro Area banks whose debt dominates the IG market. Chart 12Euro Area Corporate Bond Rally Has Stalled Chart 13Euro Area Valuations Are Not That Cheap The rise in Euro Area corporate credit spreads comes at a time when investors have grown increasingly concerned about a potential tapering of the ECB's QE when the current program expires in March of next year. As we discussed in our previous Weekly Report, we expect the ECB to announce in December an extension of the government bond QE to at least September 2017, likely with some additional changes to the rules of the QE program to avoid hitting any self-imposed purchase limits.5 This could help keep spreads anchored near current levels, all else equal. Of course, all else is never equal, and the liquidity story can be trumped by expensive valuations, as we currently see in U.S. junk bonds. Using the same metrics for U.S. IG and HY credit spreads that we presented earlier shows that both the breakeven spread for Euro Area IG, and the default-adjusted spread for Euro Area HY, are below the long-run mean (Chart 13). Euro Area junk valuations are not as stretched as U.S. junk valuations on this basis, but they are hardly cheap. A similar story exists when looking at Euro Area IG corporates grouped by credit rating, with spread curves looking as flat as the U.S. curves shown earlier (Chart 14). Our Euro Area IG sector relative value model (Table 1 on Page 11) is also showing a handful of sectors with comparatively cheap spreads, ranging from commodity-focused industries (Energy, Metals & Mining) to financial groups (Insurers, Banks). However, the "cheapness" in the latter likely represents some degree of risk premium on Euro Area banks, whose poor profitability and capital adequacy issues are now well known to investors. Euro Area bank spreads may stay cheaper for longer until those problems begin to be addressed. Chart 14Euro Area Credit Spread Curves Are Flat Table 1Euro Area Investment Grade Corporate Sector Spread Valuations One final note on the relative value between Euro Area and U.S. corporates: the bottom-up Corporate Health Monitors for both regions that we introduced earlier this year continue to show gaps favoring Euro Area IG over U.S. equivalents (Chart 15), and U.S. HY over Euro Area equivalents (Chart 16). The relative balance sheet trends are showing up in the relative investment performance across the Atlantic, with Euro Area IG starting to outperform U.S. IG, and Euro Area HY lagging the returns in U.S. HY. We continue to recommend allocations based on these relative valuation trends, keeping the lightest weighting on Euro Area junk bonds that score poorly on all relative balance sheet metrics. Chart 15Favor Euro Area IG Over U.S. IG Chart 16Euro Area Junk Is Unattractive Vs. The U.S. Bottom Line: Euro Area corporate bonds are not as expensive as U.S. equivalents, but are by no means cheap. The likely extension of the ECB QE program until at least the latter half of 2017 will help keep valuations at rich levels, especially for Investment Grade issuers where the ECB is directly buying bonds. Stay up in quality in Euro Area corporates, favoring Investment Grade over High-Yield. Robert Robis, Senior Vice President Global Fixed Income Strategy rrobis@bcaresearch.com 1 Please see BCA Global Fixed Income Strategy/U.S. Bond Strategy Weekly Report, "A Note On The Long-Term Outlook For Global Bonds", dated July 27, 2016, available at gfis.bcaresearch.com and usbs.bcaresearch.com 2 A neutral reading of the MCI is the zero line is consistent with a U.S. economy without any output gap, growing at its potential rate, and with unemployment at full employment levels. 3 Please see BCA U.S. Bond Strategy Special Report, "Don't Chase The Rally In Junk", dated Nov 1, 2016, available at usbs.bcaresearch.com 4 Source: Thomson Reuters I/B/E/S 5 Please see BCA Global Fixed Income Strategy Weekly Report, "The ECB's Next Move: Extend & Pretend", dated Oct 25, 2016, available at gfis.bcaresearch.com The GFIS Recommended Portfolio Vs. The Custom Benchmark Index Recommendations Duration Regional Allocation Spread Product Tactical Trades Yields & Returns Global Bond Yields Historical Returns
Beyond early last century's military rearmament, the idea of militarily outspending opponents was very evident in the early-1960s when U.S. defense spending surged by 20% on a year-over-year basis. If our hypothesis that a global arms race will continue to heat up in coming years pans out, then owning global (but especially U.S.) defense stocks as a structural play will pay handsome dividends. The early-1960s experience in U.S. aerospace & defense (A&D) stocks is the closest stock market parallel we found in our analysis (given data constraints). Then, relative performance was up over 100% in a span of four years, as U.S. A&D industrial production (IP) swelled to a 20% per annum clip with utilization rates running at 95%. A&D factories were humming, racing to fulfill orders as U.S. military expenditures boomed. That demand surge translated into a jump in sector sales and given the industry's high operating leverage, earnings and book values soared. The chart shows that from trough to peak, sector EPS rose by more than 400%, margins expanded from sub 2% to nearly 8%, and book value doubled. That stellar performance justified initial valuation premiums at the time. Using that period as a guide would imply that there is ample upside left for relative performance of the BCA U.S. defense index (that is a pure play on global defense spending). Bottom Line: Stay overweight the BCA U.S. defense index (LMT, GD, RTN, NOC, LLL), and please see yesterday's Special Report for additional details.
GAA DM Equity Country Allocation Model The model significantly reduced the weight of France by six percentage points due to change in liquidity condition, the other downgrade, albeit much smaller, was the U.S. All other countries had been upgraded as a result, with Germany being the largest beneficiary. Japan and U.K. remain the two largest underweights (Table 1). Table 1Model Allocation Vs. Benchmark Weights As shown in Table 2 and Chart 1, Chart 2 and Chart 3, the overall model outperformed the MSCI World benchmark by 27 basis points (bps) in October, driven completely by the Level 2 model (as U.K and Australia underperformed the euro area). The Level 1 model was in line with the benchmark. Since going live, the overall model performed slightly better than its benchmark. Please see also on the website http://gaa.bcaresearch.com/trades/allocation_performance. Table 2Performance (Total Returns In USD) Chart 1GAA DM Model Vs. MSCI World Chart 2GAA U.S. Vs. Non U.S. Model (Level 1) Chart 3GAA Non U.S. Model (Level 2) Table 3Allocations Table 4Performance Since Going Live Chart 4Overall Model Performance For more details on the models, please see the January 29th, 2016 Special Report "Global Equity Allocation: Introducing the Developed Markets Country Allocation Model". http://gaa.bcaresearch.com/articles/view_report/18850 GAA Equity Sector Selection Model The GAA Equity Sector Selection Model (Chart 4) is updated as of October 31, 2016. The momentum component has shifted Financials from underweight to overweight. For mode details on the model, please see the Special Report "Introducing the GAA Equity Sector Selection Model," July 27, 2016 available at https://gaa.bcaresearch.com. Xiaoli Tang, Associate Vice President xiaoli@bcaresearch.com Patrick Trinh, Senior Analyst patrick@bcaresearch.com Aditya Kurian, Research Analyst adityak@bcaresearch.com